Oculis CEO Riad Sherif MD to Participate in Glaucoma 360 New Horizons Forum

LAUSANNE, Switzerland, January 31st, 2023 – Oculis S.A., (‘Oculis’) a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces that its Chief Executive Officer, Riad Sherif, M.D., will be participating in the Glaucoma 360 New Horizons Forum in San Francisco, California, on Friday February 3, as a panelist in The Future in Vision Restoration and Neuroprotection session.

Time: 10:45-11:55 PST / 19:45-20:55 CET

Speakers:

Wiley Chambers, M.D., Director, Division of Ophthalmology, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration (FDA)

Nancy J. Newman, M.D., LeoDelle Jolley Chair in Ophthalmology, Professor of Ophthalmology and Neurology and Instructor in Neurological Surgery, Emory University School of Medicine; Director of Neuro-Ophthalmology, Emory Eye Center

José-Alain Sahel, M.D., Distinguished Professor and Chairman, Department of Ophthalmology, University of Pittsburgh School of Medicine

Riad Sherif, M.D., Oculis CEO

Moderators:

Kimberly Gokoffski, M.D., PhD, Assistant Professor, Clinical Ophthalmology and Associate Director of Research, Institute for Technology and Medical Systems, Keck School of Medicine, University of Southern California

Jeffrey Goldberg, M.D., PhD, Professor and Chair of Ophthalmology, Byers Eye Institute, Stanford University

Now in its 12th year, the Glaucoma 360 New Horizons Forum unites key clinical, industry, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment. Presented by the Glaucoma Research Foundation, this annual catalyst meeting is designed to bring the essential components together in order to speed the translation of new ideas into clinical practice. The event is part of Glaucoma 360, the annual three-day event uniting research, industry and philanthropy to prevent vision loss from glaucoma and speed the cure.